{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=35", "query": { "intervention": "Open Label Extension Study", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 2082, "total_pages": 209, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T09:04:35.220Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07570654", "title": "Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "PTSD - Post Traumatic Stress Disorder", "PTSD", "PTSD Symptoms", "PTSD, Post Traumatic Stress Disorder" ], "interventions": [ { "name": "COMP360 psilocybin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "COMPASS Pathways", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2026-09", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-11-02T09:04:35.220Z", "location_count": 9, "location_summary": "Tucson, Arizona • Miami, Florida • Orlando, Florida + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Eden Prairie", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07570654" }, { "nct_id": "NCT02736188", "title": "Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Inclusion Body Myopathy", "Distal Myopathy With Rimmed Vacuoles", "Distal Myopathy, Nonaka Type", "GNE Myopathy", "Quadriceps Sparing Myopathy" ], "interventions": [ { "name": "Aceneuramic Acid Extended-Release Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ultragenyx Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2016-05-02", "completion_date": "2018-01-10", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-11-02T09:04:35.220Z", "location_count": 5, "location_summary": "Los Angeles, California • Orange, California • St Louis, Missouri + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02736188" }, { "nct_id": "NCT02677805", "title": "Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glabellar Frown Lines" ], "interventions": [ { "name": "Botulinum Toxin A", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Botulinum Toxin A - Open Label", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Croma-Pharma GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 251, "start_date": "2016-03-30", "completion_date": "2017-11-03", "has_results": true, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-11-02T09:04:35.220Z", "location_count": 7, "location_summary": "Encinitas, California • Aventura, Florida • Sarasota, Florida + 4 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Hillsborough", "state": "New Jersey" }, { "city": "Mount Kisco", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02677805" }, { "nct_id": "NCT00228553", "title": "Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Excessive Daytime Sleepiness", "Narcolepsy", "Obstructive Sleep Apnea/Hypopnea Syndrome", "Chronic Shift Work Sleep Disorder" ], "interventions": [ { "name": "Armodafinil 100 to 250 mg/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cephalon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 743, "start_date": "2004-05", "completion_date": "2006-07", "has_results": true, "last_update_posted_date": "2013-07-19", "last_synced_at": "2026-11-02T09:04:35.220Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00228553" }, { "nct_id": "NCT05337553", "title": "A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spinal Muscular Atrophy", "Neuromuscular Diseases", "SMA" ], "interventions": [ { "name": "taldefgrobep alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "4 Years to 21 Years" }, "enrollment_count": 269, "start_date": "2022-07-06", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-11-02T09:04:35.220Z", "location_count": 30, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05337553" }, { "nct_id": "NCT00853762", "title": "Atacicept in Multiple Sclerosis Extension Study, Phase II", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Atacicept 25 mg", "type": "DRUG" }, { "name": "Atacicept 75 mg", "type": "DRUG" }, { "name": "Atacicept 150 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 74, "start_date": "2009-03", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2017-03-20", "last_synced_at": "2026-11-02T09:04:35.220Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Northbrook, Illinois • East Lansing, Michigan + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Northbrook", "state": "Illinois" }, { "city": "East Lansing", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00853762" }, { "nct_id": "NCT04597632", "title": "An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "brolucizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 248, "start_date": "2020-12-16", "completion_date": "2023-03-28", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-11-02T09:04:35.220Z", "location_count": 5, "location_summary": "Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04597632" }, { "nct_id": "NCT06663358", "title": "A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "Pegunigalsidase-alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chiesi Farmaceutici S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-11-06", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-11-02T09:04:35.220Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06663358" }, { "nct_id": "NCT06424236", "title": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alzheimers Disease", "Dementia", "Alzheimers Disease, Familial" ], "interventions": [ { "name": "Gantenerumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 73, "start_date": "2020-06-03", "completion_date": "2023-11-13", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-11-02T09:04:35.220Z", "location_count": 8, "location_summary": "Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06424236" }, { "nct_id": "NCT00074971", "title": "A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "Fabrazyme (agalsidase beta)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 58, "start_date": "1999-10", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-11-02T09:04:35.220Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Coral Springs, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074971" } ] }